Novavax Inc (NVAX) (Q3 2026) Earnings Call Highlights: Sanofi Milestone Lifts Revenue Outlook ...

Q: What drove the $145 million increase to the full-year 2026 revenue framework? A: CFO Jim Kelly said $125 million came from the Sanofi Phase 3 trial initiation milestone, with the remaining $20 million split evenly: $10 million from product sales ($5 million Nuvaxovid legacy APA deliveries and $5 million Matrix-M adjuvant sales on strong partner demand, which is running about $15 million above expected future run rate due to order timing and manufacturing site qualification), and $10 million from adjusted licensing royalties, primarily a non-cash deferred royalty tied to SKBio's prior sales to the Korean government.

Q: What is the target product profile for the C. Diff vaccine candidate, and how does it differ from Pfizer's program? A: Head of R&D Dr. Bob Walker said Novavax aims to differentiate on tolerability (leveraging Matrix-M's known profile), immunogenicity including mucosal IgA responses, and breadth of strain protection, with a construct designed to cover over 90% of circulating strains. Unlike Pfizer's toxin-focused approach, Novavax targets both toxin and non-toxin antigens. Walker confirmed a lead candidate has been selected, with clinical entry as early as 2027, and said the company is watching Pfizer's Phase 3 closely to learn from its successes and failures.

Q: How is Sanofi's commercial launch of Nuvaxovid progressing in the U.S., and what is the outlook for market share? A: Chief Strategy Officer Elaine O'Hara said Sanofi has kicked off the 2026-2027 season with expanded awareness efforts positioning Nuvaxovid as the only non-mRNA COVID vaccine option, including availability at CVS, Walmart and Costco, retailer pilots showing strong share and reorders, direct-to-consumer campaigns with USA Pickleball and NBA champion Karl-Anthony Towns, and a seasoned vaccine sales force. She said Nuvaxovid is promotionally sensitive and the company expects awareness, access and adoption to build season upon season as Sanofi methodically builds meaningful market share.

Q: What operational work remains before the $75 million Sanofi tech transfer milestone is earned in mid-2027? A: Chief Strategy Officer Elaine O'Hara said Novavax is working closely with Sanofi and transitioning through most of the activities required for the tech transfer to occur by mid-2027, with nothing untoward in the process. She added the company is pleased with the opportunity to transfer its technology on that timeline.

Q: What evidence or milestones typically move an MTA collaboration into a paid license, and how many evaluations are approaching that decision point? A: CEO John Jacobs said there is no one-size-fits-all answer since each partner has different needs, and Matrix-M is being explored across a wide array of infectious disease targets plus early oncology work. He emphasized the strategy is to maximize "shots on goal," acknowledging not every MTA will convert to a deal or every experiment succeed, but that a broad set of opportunities with multiple partners increases the odds of significant long-term growth. Chief Strategy Officer Elaine O'Hara added partner preclinical testing is ongoing with a remarkable level of interest.

Q: What is the potential for Matrix-M in personalized cancer vaccines, and what combinations are being explored? A: Head of R&D Dr. Bob Walker said Novavax is looking broadly across oncology, including both off-the-shelf and personalized approaches, and would not rule out either. The company is studying Matrix-M alone and in combination with immunomodulators including TLR agonists and checkpoint inhibitors, with survival studies in animal models underway. Chief Strategy Officer Elaine O'Hara added the goal is to generate data showing how Matrix-M acts within the tumor microenvironment to leverage with potential partners.

Q: How does Novavax plan to address C. Diff recurrence, and is mumps a potential Matrix-M target? A: Head of R&D Dr. Bob Walker said translational models for recurrence have been incorporated into the preclinical program, calling recurrence a high bar but one of the endpoints being examined. On mumps, CEO John Jacobs said the company remains open-minded and applies a rigorous internal process assessing market potential, unmet need, probability of technical success and trade-offs before pursuing new disease areas, thanking the analyst for the suggestion.

Q: Will data on adding Matrix-M to existing flu, RSV and pneumococcal vaccines be made public, and are partner discussions underway? A: Head of R&D Dr. Bob Walker said the company is actively investigating Matrix-M with a list of candidates and intends to use the data thoughtfully, primarily under CDA with prospective partners and selectively through publications, but likely not on earnings calls. Chief Strategy Officer Elaine O'Hara added Novavax has been generating data for several years on improving already-marketed vaccines and expects to engage partners as those datasets mature. CEO John Jacobs noted the data can show partners whether Matrix-M improves immunogenicity or lowers manufacturing costs.

Q: How should investors view the 2029 non-GAAP breakeven target, and how much depends on the Sanofi combination vaccine launch? A: CFO Jim Kelly said the U.S. combination launch and its $225 million milestone were the primary contributor to profitability timing, but not the only mechanism. He pointed to the $150 million-$200 million non-GAAP R&D and SG&A target by 2028, paying off Gavi and UK APA-era liabilities by Q1 2029, growing Nuvaxovid royalties as Sanofi builds the market, and milestones from existing or future partnerships. He said Sanofi's public statements on U.S. Phase 3 initiation in 2027 raise the probability of the launch and allow investors to ascribe more value to future cash flows

For the complete transcript of the earnings call, please refer to the full earnings call transcript .